Merck & Co's Irish project receives extra €20 million
This article was originally published in Scrip
Merck Sharp & Dohme has announced an additional €20 million investment for the first phase of construction of the company's new vaccines and biologics facility in Carlow, Ireland. This brings the total investment for the project to €220 million, the company says.
You may also be interested in...
"Unscrupulous traders" are likely to begin selling Tamiflu (oseltamivir) and Relenza (zanamivir) counterfeits if the swine flu situation escalates, the Royal Pharmaceutical Society of Great Britain (RPSBG) has warned. The alert comes in a letter to pharmacists providing information on the swine flu outbreak.
The Innovative Medicines Initiative Joint Undertaking (IMI JU) has agreed to fund the PROTECT project (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium).
Johnson & Johnson has reclaimed the top spot in the 10th Annual Harris Interactive Quotient Study, marking it as having the best reputation of the 60 most visible companies in the US.